Vanguard Group Inc A Tyr Pharma Inc Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,652,157 shares of LIFE stock, worth $5.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,652,157

Previous 2,368,454 11.98%

Holding current value

$5.3 Million

Previous $3.34 Million 54.87%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.42 - $2.02 $402,858 - $573,080	283,703 Added 11.98%	2,652,157 $5.17 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $1.51 $94,181 - $128,120	84,848 Added 3.72%	2,368,454 $3.34 Million
Q3 2023 Nov 14, 2023	SELL	$1.55 - $2.23 $26,517 - $38,150	-17,108 Reduced 0.74%	2,283,606 $3.61 Million
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.57 $355,106 - $530,594	206,457 Added 9.86%	2,300,714 $4.97 Million
Q1 2023 May 15, 2023	BUY	$1.88 - $2.5 $1.79 Million - $2.39 Million	954,131 Added 83.69%	2,094,257 $4.4 Million

Q4 2022 Feb 10, 2023	BUY	$2.02 - $2.49 $1,197 - $1,476	593 Added 0.05%	1,140,126 $2.5 Million
Q1 2022 May 13, 2022	BUY	$4.75 - $7.54 $125,124 - $198,618	26,342 Added 2.37%	1,139,533 $6.1 Million
Q4 2021 Feb 14, 2022	BUY	$7.29 - $9.5 $1.51 Million - $1.96 Million	206,450 Added 22.77%	1,113,191 $8.32 Million
Q3 2021 Nov 12, 2021	BUY	$4.22 - $12.48 $1.31 Million - $3.89 Million	311,539 Added 52.34%	906,741 $8.23 Million
Q2 2021 Aug 13, 2021	BUY	$3.62 - $4.88 $2.15 Million - $2.9 Million	595,202 New	595,202 $2.9 Million

Others Institutions Holding LIFE

# of Institutions

Shares Held

33.5M

Call Options Held

7.5K

Put Options Held

3.2K

View Full List

About aTYR PHARMA INC

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $57.3M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

More about LIFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc A Tyr Pharma Inc Transaction History